It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dietary protein dilution (DPD) promotes metabolic-remodelling and -health but the precise nutritional components driving this response remain elusive. Here, by mimicking amino acid (AA) supply from a casein-based diet, we demonstrate that restriction of dietary essential AA (EAA), but not non-EAA, drives the systemic metabolic response to total AA deprivation; independent from dietary carbohydrate supply. Furthermore, systemic deprivation of threonine and tryptophan, independent of total AA supply, are both adequate and necessary to confer the systemic metabolic response to both diet, and genetic AA-transport loss, driven AA restriction. Dietary threonine restriction (DTR) retards the development of obesity-associated metabolic dysfunction. Liver-derived fibroblast growth factor 21 is required for the metabolic remodelling with DTR. Strikingly, hepatocyte-selective establishment of threonine biosynthetic capacity reverses the systemic metabolic response to DTR. Taken together, our studies of mice demonstrate that the restriction of EAA are sufficient and necessary to confer the systemic metabolic effects of DPD.
Dietary protein dilution, where protein is reduced and replaced by other nutrient sources without caloric restriction, promotes metabolic health via the hepatokine Fgf21. Here, the authors show that essential amino acids threonine and tryptophan are necessary and sufficient to induce these effects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Monash University, Department of Biochemistry and Molecular Biology, Metabolism, Diabetes and Obesity Program, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 University of Melbourne, Department of Medicine (Austin Health), Heidelberg, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 University Hospital Heidelberg, Department of Internal Medicine III, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Center for Cardiovascular Research (DZHK), Partner sites Kiel and Heidelberg, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237)
4 University of Sydney, Charles Perkins Centre, School of Life and Environmental Sciences, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
5 Monash University, Biomedical Proteomics and Metabolomics Facility and the Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
6 Monash University, Biomedical Proteomics and Metabolomics Facility and the Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Monash Institute of Pharmaceutical Sciences, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
7 Saarland University, Institute for Biochemistry, Centre for Human and Molecular Biology (ZHMB), Saarbrücken, Germany (GRID:grid.11749.3a) (ISNI:0000 0001 2167 7588)
8 Industriepark Hoechst, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (GRID:grid.11749.3a)
9 University of Copenhagen, Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
10 Monash University, School of Biological Sciences, School of Life and Environmental Sciences, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
11 German Cancer Research Center, Division of Chronic Inflammation and Cancer, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
12 Australian National University, Research School of Biology, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
13 German Center for Cardiovascular Research (DZHK), Partner sites Kiel and Heidelberg, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); University of Kiel, Department of Internal Medicine III, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)